Tpa Clot Agent
Tpa Clot Buster Dangers
Vfcasino win loss. Inserted the gene for human tPA (tissue plasminogen activator), a common clot-busting agent, into a healthy leg vein in rabbits. The vein, which began pumping out large quantities of tPA, was then used as a bypass for an adjacent artery constricted by a blood.
The third agent is tissue plasminogen activator (tPA), a medication discovered around 1980 and originally derived from human uterine tissue. TPA has been used successfully to dissolve clots, providing useful therapy for deep vein thrombosis (DVT), heart attack, pulmonary embolism and stroke. The biggest drawback of this medicine is its high cost. TPA is a medication that dissolves blood clots. It is called a thrombolytic agent or more commonly referred to as the ‘clot buster.’ It is an intravenous or IV medication usually given through a catheter inserted into a vein in the arm.
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin. There is presently no FDA-approved pharmacotherapy for PB, but acute exacerbations of the illness are often treated with inhaled tissue plasminogen activator (tPA). To date, this is done somewhat anecdotally because there has been no safety or efficacy testing of this treatment. In addition, there is presently no reliable surrogate marker of adverse drug events. Nevertheless, in the absence of inhaled tPA treatment, PB-induced respiratory distress can be severe, often warranting urgent or emergent bronchoscopy for cast removal, or can sometimes result in respiratory failure. As such there is a significant unmet need for safety and efficacy testing of inhaled tPA and for biomarkers of drug response.
Objectives and Endpoints: The objectives of this protocol are to: 1) test the safety and efficacy of an inhaled tPA regimen in children with PB; and 2) identify potential candidate biomarkers of inhaled tPA drug response. Safety endpoints will consist of the development of new, active bleeding that is systemic and/or pulmonary and/or new hematuria (defined as gross hematuria). Secondary endpoints of efficacy will also be measured (e.g., frequency of cast production). Urine and blood will also be collected for the development of potential biomarkers of inhaled tPA drug response.
Tpa Clot Buster Side Effects
Funding source- FDA OOPD
